Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP2E1 | P05181 | 11/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 11/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 11/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.51 |
| ▸ | ATP4A | P20648 | 1/20 | 0.51 |
| ▸ | ATP4B | P51164 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475400 | 0.85 | CYP2E1 (0.57) | HTTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL6484650 | 0.82 | NPC1 (0.61) | HTTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL6475837 | 0.81 | CYP2E1 (0.57) | HTTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL6475037 | 0.81 | CYP2E1 (0.58) | HTTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL15693614 | 0.81 | SMN1; SMN2 (0.67) | HTTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL15693621 | 0.79 | NPC1 (0.81) | SMN1; SMN2NPC1RAB9ALMNATP53 | |
| SCHEMBL10711880 | 0.79 | CYP2E1 (0.55) | HTTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL10701069 | 0.78 | NPC1 (0.51) | SMN1; SMN2NPC1RAB9ALMNATP53 | |
| SCHEMBL15693618 | 0.78 | NPC1 (0.69) | SMN1; SMN2NPC1RAB9ALMNATP53 | |
| SCHEMBL10703251 | 0.78 | CYP2E1 (0.52) | HTTSMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0204215-B1 | 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines | G.D. Searle & Co. (US) | 1993-08-11 | — | — | EP | disclosed |
| EP-0204215-A1 | 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines | G.D. Searle & Co. (US) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | HTT 635/4885SMN1; SMN2 4616/4885NPC1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.